Verona Pharma stock surges 515% with strong technicals and analyst support

From Yahoo Finance: 2025-06-24 10:15:00

Verona Pharma (VRNA) has shown exceptional technical strength, hitting a new high in morning trading on June 24 with a 100% technical “Buy” signal from Barchart. The stock has surged 515% over the past year, with solid fundamentals and bullish analyst sentiment supporting VRNA’s rise. Valued at $7.87 billion, Verona Pharma is a clinical-stage biopharmaceutical company researching and developing therapeutic drugs for respiratory diseases in the UK and North America.

Shares of Verona hit a new 52-week high at $98.21 on June 24, maintaining a strong technical “Buy” signal with a Weighted Alpha of +474.59. The stock is trading above its 20, 50, and 100-day moving averages, making 12 new highs and gaining 28.7% in the last month. Revenue is projected to grow 833.62% this year, with earnings estimated to increase 156.67%. Wall Street analysts are moderately bullish on VRNA, with MorningStar believing the stock is 55% overvalued.

Verona Pharma has the support of both the market and individual investors, with 10 “Strong Buy” opinions from Wall Street analysts. However, MorningStar suggests caution due to the stock’s volatility and speculative nature. With a significant increase in price appreciation, VRNA remains a high-risk investment that requires strict risk management and stop-loss strategies.



Read more at Yahoo Finance: Up 515%, Watch This Biopharma Breakout